Berberine Derivative B68 Promotes Tumor Immune Clearance by Dual‐Targeting BMI1 for Senescence Induction and CSN5 for PD‐L1 Degradation

T cells. These findings provide a scientific basis for developing a new tumor treatment strategy based on senescence induction and lay the foundation for further preclinical research.